Citadel Advisors
AIMT

Citadel Advisors’s Aimmune Therapeutics AIMT Stock Holding History

Citadel Advisors’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-16,600
Closed -$572K – 11889
2020
Q3 		$572K Sell
16,600
-32,000
-66% -$682K ﹤0.01% 7058
2020
Q2 		$812K Sell
48,600
-55,300
-53% -$939K ﹤0.01% 6215
2020
Q1 		$1.5M Sell
103,900
-33,800
-25% -$864K ﹤0.01% 4622
2019
Q4 		$4.61M Sell
137,700
-33,000
-19% -$923K ﹤0.01% 3178
2019
Q3 		$3.57M Buy
170,700
+92,600
+119% +$1.89M ﹤0.01% 3580
2019
Q2 		$1.63M Buy
78,100
+39,400
+102% +$811K ﹤0.01% 4875
2019
Q1 		$865K Sell
38,700
-8,900
-19% -$210K ﹤0.01% 5848
2018
Q4 		$1.14M Buy
47,600
+35,800
+303% +$926K ﹤0.01% 5114
2018
Q3 		$322K Sell
11,800
-12,000
-50% -$339K ﹤0.01% 7450
2018
Q2 		$640K Buy
+23,800
New +$728K ﹤0.01% 5977

Citadel Advisors's AIMT Position: Q4 2020 in Review

Citadel Advisors sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 75,551 shares — an estimated $2.6M sold.

Citadel Advisors first reported a position in AIMT in Q2 2016 and held it in 17 quarters. The position peaked at $13.9M in Q3 2017. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Citadel Advisors reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Citadel Advisors sold 75,551 Aimmune Therapeutics shares in Q4 2020, an estimated $2.6M.
  • Citadel Advisors first reported a position in Aimmune Therapeutics in Q2 2016 and held it in 17 quarters.
  • Citadel Advisors's Aimmune Therapeutics position peaked at $13.9M in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.